| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 30 May 2025 | 22 May 2025 |
| Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve This is to intimate that the meeting of the Board of Directors of the Company is scheduled to be held on Friday 30th May 2025 to transact the following business: 1. To consider and approve the Audited Financial statement for the quarter and year ended 31st March 2025. 2. Any other matter with consent of the Chair This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 30th May, 2025 have passed the following resolution. 1. The Board of Directors of the Company has considered and approved the Standalone Audited Financial Results for the quarter and year ended 31st March, 2025 along with the, Statement of Asset and Liabilities, Result, Cash flow, Audit Report, declaration on unmodified opinion, MD/CFO certification. (As Per BSE Announcement Dated on: 30/05/2025) | ||
| Board Meeting | 23 May 2025 | 23 May 2025 |
| Allotment of Convertible Warrants pursuant to Preferential Issue. | ||
| Board Meeting | 14 Feb 2025 | 6 Feb 2025 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve DEcember Quarterly financial result outcome (As Per Bse Announcement Dated on 14.02.2025) | ||
| Board Meeting | 2 Jan 2025 | 2 Jan 2025 |
| Reg 30 of SEBI (Listing Obligation and Disclosure Requirements)- Resignation of Company Secretary | ||
| Board Meeting | 4 Dec 2024 | 29 Nov 2024 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/12/2024 inter alia to consider and approve Raising funds by way of Preferential issue of shares or warrants or any other method Outcome (As per BSE Announcement Dated on 04/12/2024) | ||
| Board Meeting | 29 Nov 2024 | 26 Nov 2024 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/11/2024 inter alia to consider and approve Preferential issue or any other matter outcome (As Per BSE Announcement Dated on 29.11.2024) | ||
| Board Meeting | 14 Nov 2024 | 6 Nov 2024 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Financial result for september 2024 Outcome (As per BSE Announcement dated on 14/11/2024) | ||
| Board Meeting | 1 Oct 2024 | 25 Sep 2024 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/10/2024 inter alia to consider and approve Allotment Outcome (As Per BSE Announcement Dated on: 01/10/2024) | ||
| Board Meeting | 14 Aug 2024 | 6 Aug 2024 |
| AAREY DRUGS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Unaudited Financial Result for June 2024 outcome (As per BSE Announcement Dated on 14/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.